<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513422</url>
  </required_header>
  <id_info>
    <org_study_id>GI-IM-LEGS-L</org_study_id>
    <secondary_id>NHMRC 402511</secondary_id>
    <secondary_id>NHMRC 402781</secondary_id>
    <nct_id>NCT00513422</nct_id>
  </id_info>
  <brief_title>The Long-term Evaluation of Glucosamine Sulphate Study</brief_title>
  <acronym>LEGS</acronym>
  <official_title>The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine if the dietary supplements, glucosamine
      sulphate and/or chondroitin can limit or reduce structural disease progression whilst
      providing symptomatic benefit in people with osteoarthritis (OA) of the knee.

      The specific hypotheses to be tested in the proposed double blind, placebo-controlled,
      randomised clinical trial are that, compared to participants allocated to placebo,
      participants allocated to either or both of these dietary supplements will demonstrate:

        -  reduced medial tibio-femoral joint space narrowing at 2 years AND;

        -  reduced knee pain over 1 year

      These benefits will be achieved by participants allocated to glucosamine sulphate and/or
      chondroitin (the study treatments) without concomitant:

        -  increased use of analgesics

        -  reduced health-related quality of life

        -  reduced participation in leisure-time physical activity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LEGS study is a double blind, placebo-controlled randomised clinical trial using a 2 x 2
      factorial design. Participant will be randomly allocated to one of the four possible
      treatment combinations:

        -  Glucosamine and Chondroitin (double active)

        -  Placebo Glucosamine and Chondroitin

        -  Glucosamine and Placebo Chondroitin

        -  Placebo Glucosamine and Placebo Chondroitin (double placebo)

      Each allocation involves taking 4 study treatment capsules once a day for two years.

      A total of 600 participants with symptomatic knee OA will be recruited by general media
      advertising and by General Practitioners through the New South Wales Divisions of general
      practice.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medial tibio-femoral joint space narrowing (mm)</measure>
    <time_frame>MRI (1 year) Radiographs (2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee pain (11 point Likert scale)</measure>
    <time_frame>Bimonthly for 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC</measure>
    <time_frame>1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients global assessment</measure>
    <time_frame>Bimonthly for 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total NSAIDs use</measure>
    <time_frame>Bimonthly for 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status (SF-12v2)</measure>
    <time_frame>1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness (cost per OMERACT-OARSI responder)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leisure time physical activity</measure>
    <time_frame>1 year, 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucosamine sulfate 1500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chondroitin sulfate 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching glucosamine/chondroitin placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosamine sulphate and chondroitin</intervention_name>
    <description>Glucosamine: Two 750mg capsules once daily for two years;
Chondroitin: Two 400mg capsules once daily for two years.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glucosamine</other_name>
    <other_name>Chondroitin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosamine sulphate</intervention_name>
    <description>Glucosamine: Two 750mg capsules once daily for two years;
Placebo Chondroitin: Two capsules once daily for two years.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Glucosamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chondroitin sulphate</intervention_name>
    <description>Chondroitin sulphate: Two 400mg capsules once daily for two years;
Placebo glucosamine: Two capsules once daily for two years.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Chondroitin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsules for glucosamine and chondroitin</intervention_name>
    <description>Two placebo glucosamine capsules once daily for two years;
Two placebo chondroitin capsules once daily for two years.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Double placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Knee pain, or taking NSAIDs/ analgesia for knee pain on most days past month

          -  Knee pain 4-10 on 10cm VAS

          -  Medial tibio-femoral compartment joint space narrowing in symptomatic knee

        Exclusion Criteria:

          -  Unstable diabetes

          -  &lt;2mm medial tibio-femoral compartment joint space width
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Fransen, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sydney, Faculty of Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Day, MB, BS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Bridges-Webb, MB, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal College of General Practitioners</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Edmonds, MB,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robyn Norton, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute, University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Woodward, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute, University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynette March, PhD, MB, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Sambrook, MB, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Bone and Joint Research, University of Sydney</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene Fransen</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>1825</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.fhs.usyd.edu.au/LEGS</url>
    <description>Study web site</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Marlene Fransen</name_title>
    <organization>University of Sydney</organization>
  </responsible_party>
  <keyword>Osteoarthritis, knee</keyword>
  <keyword>Glucosamine</keyword>
  <keyword>Chondroitin</keyword>
  <keyword>Disease progression</keyword>
  <keyword>NSAIDs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

